Search

Ventriculo-peritoneal (VP) shunt is one of the most commonly used therapeutic methods for hydrocephalus. And the incidence across the world of VP shunt complications varies from 20% to 45%. One of the rare complications is the catheter perforation of the abdominal viscera and its extrusion through the anal cavity. For the first time in the literature, this report addresses the presentation of iatrogenic perforation of the colon while inserting the peritoneal catheter of VP shunt. Here, we present the case of a 15-year-old boy who is known to have cerebral palsy and congenital hydrocephalus with a VP shunt since birth. He presented to the ER with a history of headache and episodes of vomiting and was diagnosed with VP shunt dysfunction. The patient was taken for an emergency operation for shunt revision and a new shunt was placed. Then the next day he developed signs and symptoms of peritonitis with the distal part of the catheter protruding from the anal cavity, the patient was taken to the operating room for an exploratory laparotomy, the distal catheter was removed and replaced with external ventricular drainage, intra-operatively it was shown that the catheter was inserted directly into the colon causing bowel perforation, This report raises important questions about the nature of VP shunt bowel perforation and discusses management options.

Isotretinoin is one of the first-line medications for the treatment of acne. One of the reported side effects of isotretinoin is thrombocytopenia, in addition to other abnormalities such as incomplete blood count. However, reports on thrombocytosis associated with isotretinoin are controversial. The present report discusses the case of a patient with acne vulgaris who was treated with isotretinoin and consequently suffered from isotretinoin-induced thrombocytosis. A 20-year-old female patient was diagnosed with acne vulgaris and started treatment with systemic isotretinoin (20 mg once daily) for one month. A baseline complete blood count was performed, as well as another blood count after one month of medication administration. Platelet count was recorded at each visit. The baseline platelet count was within the normal range; however, it was found to be elevated after one month of treatment. Accordingly, the medication was discontinued, and the platelet count returned to normal levels after one month, as measured during the monthly visit. The patient also experienced seizure episodes during treatment, which did not cease with the treatment discontinuation. Although isotretinoin-induced thrombocytosis is considered a rare side-effect for isotretinoin, it should be routinely monitored in high-risk patients and those undergoing surgeries. Further prospective studies on isotretinoin-induced thrombocytosis need to be conducted to gain a deeper insight into the various aspects related to the condition.